Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Cyclomethycaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.92 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.92 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.92 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclomethycaine SCHEMBL634094 | 1.00 | SCN1A (0.92) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL25345 | 0.96 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL25346 | 0.96 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL634211 | 0.95 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL634210 | 0.95 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL25713 | 0.81 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL25714 | 0.81 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL503030 | 0.80 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL503032 | 0.80 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL9224611 | 0.79 | SCN1A (0.95) | SCN1ASCN2ASCN3AHRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108872619-B | Method and device for analyzing blood sample | 希森美康株式会社 | 2024-06-11 | — | — | CN | claimed |
| CN-107848526-B | Vehicle turning control device | NTN株式会社 | 2022-03-15 | — | — | CN | claimed |
| US-20210046040-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2021-02-18 | — | — | US | claimed |
| EP-3735225-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2020-11-11 | — | — | EP | claimed |
| WO-2020012480-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2020-01-16 | — | — | WO | claimed |
| US-20140154342-A1 | SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS | SANTALIS PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | claimed |
| EP-2736504-A1 | SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS | Santalis Pharmaceuticals Inc. (US) | 2014-06-04 | — | — | EP | claimed |
| CN-103796650-A | Sandalwood oil and its uses related to skin disorders | SANTALIS PHARMACEUTICALS INC | 2014-05-14 | — | — | CN | claimed |
| WO-2013016656-A1 | SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS | SANTALIS PHARMACEUTICALS INC. (US) | 2013-01-31 | — | — | WO | claimed |
| US-8217080-B2 | Anti-infective methods and systems for treating pathogen-induced disordered tissues | CHURCH & DWIGHT CO., INC. | 2012-07-10 | — | — | US | claimed |
| US-20110245784-A1 | ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | claimed |
| US-4312865-A | Medication having penetration through cutaneous surfaces into articular and muscular areas | SZUCS MURRILL M | 1982-01-26 | — | — | US | claimed |
| US-20250120991-A1 | TOPICAL ANALGESIC | CONCEPT MATRIX SOLUTIONS (US) | 2025-04-17 | — | — | US | disclosed |
| US-12171774-B2 | Topical analgesic | CONCEPT MATRIX SOLUTIONS (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240325335-A1 | BIOLOGICALLY COMPATIBLE, BIOFILM DISRUPTING COMPOSITION AND METHODS | MICHALOW ALEXANDER E (US) | 2024-10-03 | — | — | US | disclosed |
| US-20230302028-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2023-09-28 | — | — | US | disclosed |
| EP-0040457-A2 | Agent dispenser with microporous releasing diffusor | ALZA CORPORATION (US) | 1981-11-25 | — | — | EP | disclosed |
| US-4285987-A | Process for manufacturing device with dispersion zone | ALZA CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| US-4235236-A | Device for dispensing drug by combined diffusional and osmotic operations | ALZA CORPORATION (US) | 1980-11-25 | — | — | US | disclosed |
| US-4200098-A | Osmotic system with distribution zone for dispensing beneficial agent | ALZA CORPORATION (US) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171774-B2 | Topical analgesic | TRPV1, CNR2, FAAH | SCN1A 614/4885SCN2A 790/4885SCN3A 765/4885 |
| US-20250120991-A1 | TOPICAL ANALGESIC | TRPV1, CNR2, FAAH | SCN1A 614/4885SCN2A 790/4885SCN3A 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.